These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 1354938

  • 1. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure.
    Dei Cas L, Metra M, Visioli O.
    Am J Cardiol; 1992 Sep 01; 70(6):629-34. PubMed ID: 1354938
    [Abstract] [Full Text] [Related]

  • 2. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
    van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI.
    J Am Coll Cardiol; 1993 Nov 15; 22(6):1564-73. PubMed ID: 7901256
    [Abstract] [Full Text] [Related]

  • 3. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
    Szabó BM, van Veldhuisen DJ, van der Burgh PH, Kruik J, Girbes AR, Lie KI.
    J Card Fail; 1996 Sep 15; 2(3):185-92. PubMed ID: 8891856
    [Abstract] [Full Text] [Related]

  • 4. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines.
    Van Veldhuisen DJ, Crijns HJ, Girbes AR, Tobé TJ, Wiesfeld AC, Lie KI.
    Am J Cardiol; 1991 Nov 01; 68(11):1194-202. PubMed ID: 1683146
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of ibopamine in congestive heart failure.
    van Veldhuisen DJ, Girbes AR, Crijns HJ, Smit AJ, de Graeff PA, Lie KI.
    J Auton Pharmacol; 1990 Nov 01; 10 Suppl 1():s115-21. PubMed ID: 1983005
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.
    Rajfer SI, Rossen JD, Douglas FL, Goldberg LI, Karrison T.
    Circulation; 1986 Apr 01; 73(4):740-8. PubMed ID: 3948372
    [Abstract] [Full Text] [Related]

  • 8. Effects of ibopamine on exercise-induced increase in norepinephrine in normal men.
    Girbes AR, Van Veldhuisen DJ, Grevink RG, Smith AJ, Reitsma WD.
    J Cardiovasc Pharmacol; 1992 Mar 01; 19(3):371-4. PubMed ID: 1378116
    [Abstract] [Full Text] [Related]

  • 9. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
    López-Sendón J.
    Am J Med; 1991 May 29; 90(5B):43S-49S. PubMed ID: 1675551
    [Abstract] [Full Text] [Related]

  • 10. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
    Metra M, Missale C, Spano PF, Cas LD.
    J Cardiovasc Pharmacol; 1995 May 29; 25(5):732-40. PubMed ID: 7630152
    [Abstract] [Full Text] [Related]

  • 11. Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure.
    Munger MA, Nara AR, Pospisil RA, Stoddard GJ, Schleman M.
    Pharmacotherapy; 1993 May 29; 13(3):218-23. PubMed ID: 8100627
    [Abstract] [Full Text] [Related]

  • 12. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
    Lieverse AG, Girbes AR, Van Veldhuisen DJ, Smit AJ, Zijlstra JG, Meijer S, Lie KI, Reitsma WD.
    Eur Heart J; 1995 Jul 29; 16(7):937-42. PubMed ID: 7498209
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial.
    van Veldhuisen DJ, Brouwer J, Man in 't Veld AJ, Dunselman PH, Boomsma F, Lie KI.
    Am J Cardiol; 1995 Apr 15; 75(12):796-800. PubMed ID: 7717282
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L, Metra M, Nodari S, Visioli O.
    J Cardiovasc Pharmacol; 1989 Apr 15; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.